Birth weight, breast cancer susceptibility loci, and breast cancer risk

Tamimi, Rulla M.; Λάγιου, Παγώνα; Czene, Kamila; Liu, Jing; Ekbom, Anders; Hsieh, Chung‐Cheng; Adami, Hans‐Olov; Trichopoulos, Dimitrios; Hall, Per

doi:10.1007/s10552-009-9496-7

Cited by 29 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Garcia et al [19] Antoniou et al [18] Liang et al [20] MEC-Janpanese [30] Thai [30] MEC-AA [30] Seoul [30] Searchset1 [30] Rebbeck et al [28] Prentice et al [27] Searchset3 [30] Samson et al [29] CARE-LA+LIFE [30] Taiwan [30] Zheng et al [31] Kawase et al [25] MEC-White [11] Boyarskikh et al [23] Searchset2 [30] Tamimi et al [32] Total (95% CI)…”

Section: Study or Subgroupmentioning

confidence: 99%

Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer

Jia

Cai

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Fibroblast growth factor receptor 2 is a tyrosine kinase receptor that is a member of the family of individually distinct fibroblast growth factor receptors involved in cell proliferation, invasiveness, motility, and angiogenesis. Genome-wide association studies have identified FGFR2 as a breast cancer (BC) susceptibility gene in populations of European and Asian descent. After that, a number of studies reported that the rs2981582, rs1219648, and rs2420946 polymorphism in FGFR2 has been implicated in BC risk. However, studies on the association between these polymorphism and BC remain conflicting. To derive a more precise estimation of the relationship, a meta-analysis of 46,747 cases and 87,342 controls from 16 published case-control studies was performed. Overall, significantly elevated BC risk was associated with rs2981582, rs1219648, and rs2420946 risk allele when all studies were pooled into the meta-analysis. Significant results were also observed in heterozygous and homozygous when compared with wild genotype for these polymorphisms. In the subgroup analysis by ethnicity, source of controls, significantly increased risks were found for these polymorphisms in all genetic model. In conclusion, this meta-analysis suggests that rs2981582, rs1219648, and rs2420946 polymorphisms in FGFR2 are associated with elevated BC risk.

show abstract

Section: Study or Subgroupmentioning

confidence: 99%

Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer

Jia

Cai

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In total, 18 studies involving 44,820 cases and 58,316 controls met the inclusion criteria and were used in pooled analyses (Antoniou et al, 2008;Garcia-Closas et al, 2008;Li et al, 2009;Mcinerney et al, 2009;Gorodnova et al, 2010;Latif et al, 2010;Liang et al, 2010;Tamimi et al, 2010;Campa et al, 2011;Han et al, 2011;Slattery et al, 2011;Harlid et al, 2012;Shan et al, 2012;Mizoo et al, 2013;Ottini et al, 2013;Chen et al, 2014;Elematore et al, 2014). The primary features of these investigations are shown in Table 1.…”

Section: Study Characteristicsmentioning

confidence: 99%

Increased risk of breast cancer in individuals carrying the TNRC9 rs3803662 C>T polymorphism: a meta-analysis of case-control studies

Wang

Cao

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Currently, the relationship between the trinucleotide repeat containing 9 (TNRC9) rs3803662 C>T polymorphism and risk of breast cancer (BC) is uncertain. Here, we attempted to obtain a more accurate assessment of this association by conducting a meta-analysis of all eligible case-control investigations, comprising 44,820 cases and 58,316 controls. A comprehensive search was performed to identify all suitable studies involving the TNRC9 rs3803662 polymorphism and BC risk. Pooled odds ratios (ORs) and 95% confidence intervals (95%CIs) were estimated using fixed-or random-effect models. Heterogeneity, publication bias, and sensitivity analyses were also carried out. We found that the variant T allele of rs3803662 C>T greatly increases BC risk (CT vs CC: OR = 1.14, 95%CI = 1.07-1.22, P < 0.001; TT vs CC: OR = 1.38, 95%CI = 1.25-1.53, P < 0.001; CT/TT vs CC: OR = 1.19, 95%CI = 1.11-1.28, P < 0.001; TT vs CT/CC: OR = 1.28, 95%CI = 1.19-1.38, P < 0.001). Stratified analysis based on ethnicity also revealed a markedly increased risk in Asian and Caucasian populations. Moreover, studies with hospital-based control groups showed elevated risk under the four genetic models employed, as did those using population-based controls, except under heterozygote comparison. The TNRC9 rs3803662 C>T polymorphism is greatly related to increased risk of BC, in both Asian and Caucasian populations.

show abstract

“…During the extraction of data, 38 articles were excluded, because they did not provide MAP3K1 polymorphism allele frequencies needed for OR calculation or their contents mainly associated with cancer prognosis and therapy, leaving six publications which met the inclusion criteria [10,[13][14][15][16][17]. In the study of Barnholtz-Sloan et al [15] the ORs were presented separately according to the African Americans study and Whites study.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Up to date, many studies have evaluated the potential role of MAP3K1 genotypes in breast cancer development and the risk modification of the effect by the rs889312 polymorphism of this gene [10,[13][14][15][16][17]. Antoniou et al [17] reported that the minor alleles in MAP3K1 rs889312 polymorphism were not associated with breast cancer risk in the combined sample of BRCA1 and BRCA2 mutation carriers or in BRCA1 carriers alone.…”

Section: Introductionmentioning

confidence: 99%

Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects

Yang

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Published data on the association between mitogen-activated protein kinase kinase kinase 1 (MAP3K1) gene rs889312 polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of seven eligible articles including 26,015 cases and 33,962 controls based on the search criteria were involved in this meta-analysis. We observed that the MAP3K1 rs889312 polymorphism was significantly correlated with breast cancer risk from the fixed effects model when all studies were pooled into the meta-analysis (the allele contrast model: OR 1.09, 95% CI 1.07-1.12; the homozygote codominant: OR 1.22, 95% CI 1.15-1.29; the heterozygote codominant: OR 1.07, 95% CI 1.04-1.11; the dominant model: OR 1.10, 95% CI 1.06-1.13; the recessive model: OR 1.18, 95% CI 1.12-1.25). No significant association was found in the BRCA1 mutation carriers in all genetic models. When stratified by BRCA2 mutation carriers status, statistically significantly elevated risk was found in this meta-analysis (C vs. A: OR 1.12, 95% CI 1.01-1.23; CC vs. AA: OR 1.35, 95% CI 1.06-1.71; the recessive model: OR 1.31, 95% CI 1.05-1.65). There was no evidence for significant association between MAP3K1 rs889312 polymorphism and breast cancer risk in BRCA1 and BRCA2 positive cohort for all comparison models. In conclusion, this meta-analysis suggests that the MAP3K1 rs889312 C allele is a low-penetrant risk factor for developing breast cancer, and there is limited evidence to indicate that MAP3K1 rs889312 polymorphism is associated with increased risk of breast cancer in BRCA1 mutation carriers.

show abstract

Birth weight, breast cancer susceptibility loci, and breast cancer risk

Abstract: Although our findings require confirmation, we found suggestive evidence that genetic susceptibility modifies the positive association of birth weight with breast cancer.

Cited by 29 publications

References 33 publications

Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer

Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer

Increased risk of breast cancer in individuals carrying the TNRC9 rs3803662 C>T polymorphism: a meta-analysis of case-control studies

Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects

Contact Info

Product

Resources

About